Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESMAIN study of resminostat maintenance in advanced mycosis fungoides or Sézary syndrome
NL-OMON55744Phase 2Active, not recruiting
- Sponsor
- 4SC AG
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS) comparing Resminostat maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Aug 2017; status: active, not recruiting.
02
Drugs
Resminostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NL-OMON55744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55744.